The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Dyskinesia Challenge, 2012AVP-923 for Levodopa-induced Dyskinesia in Parkinson's Disease
Objective/Rationale:
Dextromethorphan regulates glutamate and serotonin, brain chemicals that help control movements. In people with Parkinson's disease (PD), brain chemical alterations, coupled with... -
Rapid Response Innovation Awards, 2012Glycosylated Opioid Peptides For the Treatment of Levodopa-Induced Dyskinesias
Objective/Rationale:
Nearly all Parkinson's patients will eventually be treated with levodopa. However, the majority of patients will eventually develop disabling side effects known as levodopa-induced... -
Alpha-synuclein Biology Challenge, 2012Normal Role of Synuclein in Mitochondrial Bioenergetics at the Synapse
Objective/Rationale:
Decreasing levels of a-synuclein (SYN) is a promising therapeutic strategy for PD, but the safety of lowering SYN has not been established. Although the normal functions of SYN are... -
Rapid Response Innovation Awards, 2012Stimulation of Protein Clearance Mechanisms to Improve Clearance of Toxic Accumulations of Alpha-synuclein
Objective/Rationale:
Alpha-synuclein protein accumulation in the brain causes neurotoxicity in Parkinson’s disease (PD). Neural cells have a protein degradation mechanism called the... -
Novel Approaches to Drug Discovery for PD, 2012Cerium Oxide Nanoparticles in the Treatment of Parkinson’s Disease – Toxicity and Biodistribution Studies
Promising Outcomes of Original Grant:
In our prior years of funding from The Michael J. Fox Foundation, we tested the hypothesis that cerium oxide nanoparticles (CeONP) were a disease-modifying therapy... -
Research Grant, 2012Collaborative Validation of Oxidized DJ-1 Antibodies For PD Biomarker Study
Objective/Rationale:
We have developed antibodies against an oxidized form of DJ-1 using complementary approaches to be able to use them as a biomarker in PD. A common problem in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.